H.C. Wainwright analyst Andrew Fein reiterated a Buy rating on MEI Pharma (NASDAQ:MEIP) on Monday, setting a price target of $10, which is approximately 264.96% above the present share price of $2.74.
Fein expects MEI Pharma to post earnings per share (EPS) of -$0.26 for the second quarter of 2020.
The current consensus among 2 TipRanks analysts is for a Moderate Buy rating of shares in MEI Pharma, with an average price target of $9.5.
The analysts price targets range from a high of $10 to a low of $9.
In its latest earnings report, released on 12/31/2019, the company reported a quarterly revenue of $1.01 million and a net profit of -$12.11 million. The company's market cap is $290.44 million.
According to TipRanks.com, H.C. Wainwright analyst Andrew Fein is a 5-star analyst with an average return of 10.6% and a 47.1% success rate.
MEI Pharma, Inc. engages in the clinical development of therapies for cancer. Its drug candidates includes Pracinostat, an oral HDAC inhibitor that is being developed in combination with azacitidine for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Its pipeline also consists of ME-401, an oral PI3K delta inhibitor; Voruciclib, an oral CDK inhibitor; and ME-344, a mitochondrial inhibitor. The company was founded on December 1, 2000 and is headquartered in San Diego, CA.
